Showing results (611-620 of 1,087) with videos related to
Sort By:
Pageof 109
American Heart Journal|April 10, 2020
COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trialGeorgios J Vlachojannis, Rosanne F Vogel, Jeroen M Wilschut, et al.Clinical Pharmacology and Therapeutics|August 28, 2025
Impact of Race on Profiles of Platelet Reactivity and Clinical Outcomes in Clopidogrel-Treated ParticipantsLuis Ortega-Paz, Cameron D Thomas, Claudio Laudani, et al.Nature Reviews. Cardiology|July 6, 2018
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke preventionDavide Capodanno, Roxana Mehran, Marco Valgimigli, et al.Circulation. Cardiovascular Interventions|May 24, 2012
Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trialDominick J Angiolillo, Robert C Welsh, Dietmar Trenk, et al.Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|October 10, 2020
Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stentsRidhima Goel, Davide Cao, Rishi Chandiramani, et al.Circulation|December 14, 2020
Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH TrialGeorgios J Vlachojannis, Jeroen M Wilschut, Rosanne F Vogel, et al.Journal of Thrombosis and Thrombolysis|March 12, 2021
Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studiesToshiki Kuno, Bimmer Claessen, Davide Cao, et al.JAMA Cardiology|September 27, 2019
Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS TrialMariusz Tomaniak, Ply Chichareon, Yoshinobu Onuma, et al.The American Journal of Cardiology|October 9, 2007
Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary interventionMarzia Lotrionte, Giuseppe G L Biondi-Zoccai, Pierfrancesco Agostoni, et al.Journal of the American Heart Association|July 4, 2025
CYP2C19 Phenotype, P2Y12 Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel TherapyRajiv C Patel, Cameron D Thomas, Joseph S Rossi, et al.Pageof 109